“Inhaled Nitric Oxide as an Adjunctive Treatment for Cerebral Malaria in Children: A Phase II Randomized Open-Label Clinical Trial” by Mwanga-Amumpaire et al (Summer 2015 2(3):doi:10.1093/ofid/ofv111) neglected to include author Kenneth D. Block's affiliation with Harvard Medical School (#11), neglected to use subscript numbers for nitrogen in Figure 2 and Figure 3 captions (N2), and also inverted Figure 2 and Figure 3. The corrected figures and captions appear below.
Figure 2.
(A) Delivered dose of nitric oxide (NO) over 120 hours (mg/kg per hour); (B) blood methemoglobin (percentage of methemoglobin [metHb %]) in patients treated with nitrogen (N2) and NO; (C) Plasma nitrate (μM) levels; and (D) plasma nitrite (μM) levels in patients treated with N2 or NO. *P < .001 and **P < .05, NO versus N2. All data mean ± standard deviation.
Figure 3.
(A) Kaplan-Meier curves comparing survival in pediatric patients with cerebral malaria (CM) treated with nitrogen (N2) or nitric oxide (NO). P = not significant (NS). (B) Kaplan-Meier curves for resolution of coma in pediatric patients with CM, N2 vs NO; resolution of coma is defined as Blantyre coma score ≥ 3 or Glasgow coma score of ≥7; (N2 N = 39, NO N = 41). P = NS. Abbreviations: INO, inhaled NO; metHb%, percentage of methemoglobin.
The publisher apologizes for any inconvenience these errors may have caused.